Improving clinical outcomes using adoptively transferred immune cells from umbilical cord blood.

ABSTRACT: Because of the necessary immunodepletion prior to cord blood transplantation as well as the immaturity of cord blood immune cells, recipients experience a high incidence of viral infection in addition to complications observed after hematopoietic stem cell transplantation, such as relapse and graft-versus-host disease. We describe current immunotherapeutic approaches to treating these complications, including the generation of antigen-specific T cells from cord blood, redirecting cord blood T cells using chimeric antigen receptors, and generating cord blood-derived natural killer cells and regulatory T cells.

SUBMITTER: Hanley PJ 

PROVIDER: S-EPMC3178185 | biostudies-literature | 2010 Oct

REPOSITORIES: biostudies-literature